Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021; 23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Pharma has long marketed opioids in ways that contribute to opioid use disorder and deaths by overdose. Regulatory mistakes in approving and labeling new analgesics by the FDA didn’t make us safer.
AMA J Ethics. 2020; 22(8):E743-750. doi:
10.1001/amajethics.2020.743.
Annette Mendola, PhD and Richard L. Gibson, MD, MPH
Because research on the efficacy of approaches to addiction recovery is inconclusive, clinicians should recommend several, including 12-step approaches.
AMA J Ethics. 2016; 18(6):646-655. doi:
10.1001/journalofethics.2016.18.6.sect1-1606.
Jonathan M. Metzl, MD, PhD and Dorothy E. Roberts, JD
The call for structural competency encourages medicine to broaden its approach to matters of race and culture so that it might better address both individual-level doctor and patient characteristics and institutional factors.
Registries of those considered dangerous focus wrongly on those with mental illness, who account for only 4 percent of violent acts committed in the United States.
Fabian von Knoch, MD, Anthony Marchie, MD, MPhil, and Henrik Malchau, MD, PhD
An argument that national joint registries have improved outcomes for arthroplasty patients because they track device performance, reduce revision surgeries, and promote evidence-based surgery.